CD8A and neoplasm: Conversely, in 2017, Hijikata et al. conducted a phase I trial on RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors, showing potential clinical efficacy with stable disease in six out of ten patients and an increase in tumor-reactive CD8+ T cells [162].